SC Engineering, listed on the securities market, announced on 11th that its subsidiary Cellontek will begin the completion procedures for a new bio-collagen medical device factory to respond to the increasing demand in overseas markets, including China.
Cellontek plans to accelerate productivity enhancement by signing a conceptual design and validation consulting contract for the bio-collagen medical device new factory with SPK, a specialized consulting company for good manufacturing practice (GMP).
The new Cellontek bio-collagen medical device factory will have a total floor area of 16,670 square meters and aims for completion and a full-scale production start in 2026 after completing construction in the first half of last year.
Cellontek explained that upon completion of the new factory, it will secure more than five times the existing production capacity and establish a production base for bio-collagen raw materials and medical devices that meet U.S. cGMP and European EU-GMP standards.
Cellontek is a specialized company for regenerative therapy medical devices based on its proprietary bio-collagen materials registered with the U.S. Food and Drug Administration (FDA) Drug Master File (DMF). It supplies products such as intra-articular injection 'Cartizol', aesthetic filler 'Terraphil', and tendon/ligament reconstruction 'Regenseal' to domestic and overseas markets.
A representative from Cellontek said, "In preparation for the delivery of existing overseas market supply contracts, such as the launch of 'Terraphil' and 'Cartizol' in the Chinese market in the future, we will actively respond to various supply proposals in the global regenerative medicine and aesthetic surgery markets."